Redefiners Medical Guidance Session _Cycle I 2021 DAY 2 QUIZ

DEVOTE stands for

• Diabetes vascular outcome trial

• Degludec Vasculcar outcome trial

• Degludec evaluation in Vasculcar outcome trial

• Both B & C

3 Point MACE stands for

• Minor adverse cardiovascular events

• Maximum adverse cardiovascular events

• Major adopted cardiovascular events

• Major adverse cardiovascular events

DEVOTE is a

• Phase 2, multicentre, international, randomised, double-blind, active comparator-controlled, event-driven trial

• Phase 4, multicentre, international, randomised, double-blind, active comparator-controlled, event-driven trial

• Phase 3a, multicentre, international, randomised, double-blind, active comparator-controlled, event-driven trial

• Phase 3b, multicentre, international, randomised, double-blind, active comparator-controlled, event-driven trial

In DEVOTE, With Degludec how much reduction was observed in first occurrence of 3 point MACE ?

• 19%

• 11%

• 9%

• 22%

In Devote, % less risk of nocturnal severe hypoglycaemia was observed with Degludec vs Glargine?

• 53%

• 42%

• 47%

• 50%

Cost effectiveness data are used to define "VALUE"

• Resource use

• Health Impact

• Both A & B

Short term health economics model based on the values observed in the clinical trials

• Hypoglycaemic Benefit

• Weight Benefits

• Dose Reduction

• All of Above

Pollock et al 2019, Another Cost effectiveness analysis is

• To evaluate the Long-term cost-effectiveness of

  Insulin degludec versus insulin glargine U100 in the UK:

• To evaluate the Long-term cost-effectiveness of

  IDegAsp versus insulin glargine U100 in the Netherland

• To evaluate the Long-term cost-effectiveness of

  IDegAsp versus insulin glargine U100 in the UK

• To evaluate the Long-term cost-effectiveness of

  IDegAsp versus insulin glargine U100 in the Denmark

As per Pollock et al: 2019, Analysis demonstrates that over patient lifetimes, treatment with Insulin Degludec versus Glargine U100 would represent an efficient use of NHS resources in patients with T2D at high CV risk

• True

• False

In Pollock et al:2019, one of the models which captured the development of eight diabetes-related complications, death from other causes, severe hypoglycemia, insulin dosing, QALE and direct medical costs with degludec versus glargine U100 over a 40-year time horizon?

• Marlin Carlo microsimulation model

• Monte Carlo microsimulation model

• Both A & B